112 related articles for article (PubMed ID: 8691988)
41. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
42. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
43. Differential induction of peroxisomal and microsomal fatty-acid-oxidising enzymes by peroxisome proliferators in rat liver and kidney. Characterisation of a renal cytochrome P-450 and implications for peroxisome proliferation.
Sharma RK; Lake BG; Makowski R; Bradshaw T; Earnshaw D; Dale JW; Gibson GG
Eur J Biochem; 1989 Sep; 184(1):69-78. PubMed ID: 2776771
[TBL] [Abstract][Full Text] [Related]
44. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver.
Chow T; Imaoka S; Hiroi T; Funae Y
Drug Metab Dispos; 1999 Feb; 27(2):188-92. PubMed ID: 9929501
[TBL] [Abstract][Full Text] [Related]
45. Characterization of two P-450 isozymes placed in the rat CYP2D subfamily.
Ohishi N; Imaoka S; Suzuki T; Funae Y
Biochim Biophys Acta; 1993 Nov; 1158(3):227-36. PubMed ID: 8251521
[TBL] [Abstract][Full Text] [Related]
46. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
47. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
48. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
49. Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats.
Morita K; Maeda Y; Masuda M; Kazusaka A; Imaoka S; Funae Y; Fujita S
Biochem Pharmacol; 1998 May; 55(9):1405-11. PubMed ID: 10076532
[TBL] [Abstract][Full Text] [Related]
50. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
51. Effect of 3-methylcholanthrene on bunitrolol metabolism. Kinetics and immunological studies on 4-hydroxylation of bunitrolol catalyzed by two species of cytochromes P450 in rat liver microsomes.
Fujita S; Masuda M; Shimamoto Y; Hoshi H; Kariya S; Kazusaka A; Suzuki T
Drug Metab Dispos; 1996 Feb; 24(2):254-9. PubMed ID: 8742239
[TBL] [Abstract][Full Text] [Related]
52. P-450-dependent metabolism of lauric acid in alcoholic liver disease: comparison between rat liver and kidney microsomes.
Amet Y; Lucas D; Zhang-Gouillon ZQ; French SW
Alcohol Clin Exp Res; 1998 Apr; 22(2):455-62. PubMed ID: 9581653
[TBL] [Abstract][Full Text] [Related]
53. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved.
Fujimaki M
Drug Metab Dispos; 1994; 22(5):700-8. PubMed ID: 7835220
[TBL] [Abstract][Full Text] [Related]
54. Human liver debrisoquine 4-hydroxylase: test for specificity toward various monooxygenase substrates and model of the active site.
Wolff T; Distlerath LM; Worthington MT; Guengerich FP
Arch Toxicol; 1987; 60(1-3):89-90. PubMed ID: 3619650
[TBL] [Abstract][Full Text] [Related]
55. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
56. Inhibitory effect of rifampicin on the depressive action of interleukin-1 on cytochrome P-450-linked monooxygenase system.
Kurokohchi K; Yoneyama H; Nishioka M; Ichikawa Y
Metabolism; 2001 Feb; 50(2):231-6. PubMed ID: 11229434
[TBL] [Abstract][Full Text] [Related]
57. CYP2D-related metabolism in animals of the Canoidea superfamily - species differences.
Ishizuka M; Lee JJ; Masuda M; Akahori F; Kazusaka A; Fujita S
Vet Res Commun; 2006 Jul; 30(5):505-12. PubMed ID: 16755362
[TBL] [Abstract][Full Text] [Related]
58. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
59. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of dark agouti rats.
Suzuki T; Narimatsu S; Fujita S; Masubuchi Y; Umeda S
Biochem Pharmacol; 1991 Nov; 42(11):2241-4. PubMed ID: 1958240
[No Abstract] [Full Text] [Related]
60. Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein.
Masubuchi Y; Araki J; Narimatsu S; Suzuki T
Biochem Pharmacol; 1992 Jun; 43(12):2551-7. PubMed ID: 1632813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
